Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy

NCT01079325 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT01079325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01079325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy
Lead sponsor
Sangamo Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
April 30, 2016
Enrollment
170 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, diabetes mellitus, type 2, diabetic polyneuropathy